
    suspected side effects to the combination of clarithromycin and vcd (bortezomib,
    cyclophosphamide and dexamethasone)
  
['multiple myeloma']
['clarithromycin', 'placebo', 'vcd induction therapy']

        Inclusion Criteria:

          -  Myeloma diagnosis according to IMWG criteria

          -  Treatment demanding disease

          -  High-dose melphalan with stem cell support scheduled as a part of the treatment

          -  Signed informed consent given prior to any study related activities

          -  Age > 18 years

        Exclusion Criteria:

          -  Allogeneic transplantation scheduled as a part of the treatment

          -  Myeloma treatment prior to entry in the study, except radiotherapy,
             bisphosphonates/denosumab or corticosteroids for symptom control

          -  Concurrent disease making clarithromycin treatment unsuitable

          -  Positive pregnancy test (only applicable for women with childbearing potential)

          -  Known or suspected hypersensitivity or intolerance to clarithromycin

          -  Prolonged QT corrected (QTc) interval ( > 500 msec on screening ECG)

          -  Concurrent treatment with cabergoline, fluconazole, ketoconazole, pimozide,
             quetiapine, sirolimus, verapamil, tacrolimus, ergot alkaloid, simvastatin or other
             statins

          -  Uncontrolled or severe cardiovascular disease including myocardial infarction within 6
             months of enrolment, uncontrolled angina or known cardiac amyloidosis

          -  Severe renal dysfunction (estimated creatinine clearance <10 mL/min)

          -  Serious medical or psychiatric illness which, in the judgment of the investigator,
             would make the patient inappropriate for entry into the study
      